Clinicopathological Characteristics of Gastric Cancer in Iranian Patients Referred to Imam Reza Hospital During 2008 to 2017
Archives of Medical Laboratory Sciences,
Vol. 6 (2020),
20 January 2020
,
Page 1-6 (e18)
https://doi.org/10.22037/amls.v6.33309
Abstract
Background and Aim: There are a limited number of studies regarding the clinicopathological features of gastric cancer. Here, the clinicopathological features of gastric cancer including tumor type and size, degree of differentiation, tumor operability, and immunohistochemically results of E-cadherin and P53 expression was investigated in Iranian patients.
Methods: This retrospective study was performed on patients who were admitted at Imam Reza Hospital in Tehran-Iran from 2008 to 2017 with a diagnosis of gastric cancer. Required information including age, sex, type of cancer, pathology, and immunohistochemistry (IHC) results and treatment were extracted from the hospital archive.
Results: Out of 264 enrolled patients (with the mean age of 70.03±14.01 years), 180 cases were men. The frequency of intestinal-type, Diffuse-type, lymphoma and GIST tumor were 54.5%, 27.7%, 12.25% and 5.92% respectively. In addition, 67.58% and 13.83% of the tumors were undifferentiated and poorly differentiated respectively.
Surgery was less probable in less differentiated tumors (r=0.582 P=0.001). The surgery rate in GIST, intestinal-type, and Diffuse-type tumors were 100%, 57%, and 14.4%, respectively. IHC results showed that E-cadherin expression was present in 78.6, of which 50.9% were weakly positive (+1). Also, the high expression of P53 was observed in 60.7% of patients.
Conclusion: According to the data, we can conclude that poorly differentiated tumors, decreased expression of E-cadherin, and increased expression of P53 is linked to poor prognosis in Iranian patients with gastric cancer. In this regard, further clinical trials and multicenter studies should be done to evaluate the possible factors for improving the prognosis and survival rates of Iranian patients with gastric cancer.
*Corresponding Author: Shahrokh Iravani; Email: iravanishahrokh@ajaums.ac.ir
Please cite this article as: Sattartabar B, Nourian M, Samizadeh E, Mehrvar N, Jalaeikhoo H, Mehrvar A, Iravani S. Clinicopathological Characteristics of Gastric Cancer in Iranian Patients Referred to Imam Reza Hospital During 2008 to 2017. Arch Med Lab Sci. 2020;6:1-6 (e18). https://doi.org/10.22037/amls.v6.33309
- Gastric cancer
- Tumor
- Surgery
- E-cadherin
- P53
- Differentiation
How to Cite
References
Rawla P, Barsouk A. Epidemiology of gastric cancer: global trends, risk factors and prevention. Przeglad gastroenterologiczny. 2019;14(1):26.
Amirkhah R, Naderi-Meshkin H, Mirahmadi M, Allahyari A, Sharifi HR. Cancer statistics in Iran: Towards finding priority for prevention and treatment. Cancer Press. 2017;3(2):27-38.
Roshandel G, Ghanbari-Motlagh A, Partovipour E, Salavati F, Hasanpour-Heidari S, Mohammadi G, et al. Cancer incidence in Iran in 2014: results of the Iranian National Population-based Cancer Registry. Cancer epidemiology. 2019;61:50-8.
Lauren, P, The two histological main types of gastric carcinoma: diffuse and so‐called intestinal‐type carcinoma: an attempt at a histo‐clinical classification. Acta Pathologica Microbiologica Scandinavica, 1965. 64(1): p. 31-49.
Muñoz N, Correa P, Cuello C, Duque E. Histologic types of gastric carcinoma in high‐and low‐risk areas. International Journal of Cancer, 1968. 3(6): p. 809-818.
Hattori Y, Itoh H, Uchino S, Hosokawa K, Ochiai A, Ino Y, et al. Immunohistochemical detection of K-sam protein in stomach cancer. Clinical Cancer Research. 1996;2(8):1373-81.
Albertson DG, Collins C, McCormick F, Gray JW. Chromosome aberrations in solid tumors. Nature genetics. 2003;34(4):369-76.
Sadjadi A, Malekzadeh R, Derakhshan MH, Sepehr A, Nouraie M, Sotoudeh M, et al. Cancer occurrence in Ardabil: Results of a population‐based Cancer Registry from Iran. International journal of cancer. 2003;107(1):113-8.
Chen Y, Bal B, Gorski J. Calcium and collagen binding properties of osteopontin, bone sialoprotein, and bone acidic glycoprotein-75 from bone. Journal of Biological Chemistry. 1992;267(34):24871-8.
Park JW, Kim MS, Voon DC, Kim SJ, Bae J, Mun DG et al. Multi‐omics analysis identifies pathways and genes involved in diffuse‐type gastric carcinogenesis induced by E‐cadherin, p53, and Smad4 loss in mice. Molecular carcinogenesis. 2018;57(7):947-54.
Park JW, Park DM, Choi BK, Kwon BS, Seong JK, Green JE et al. Establishment and characterization of metastatic gastric cancer cell lines from murine gastric adenocarcinoma lacking Smad4, p53, and E‐cadherin. Molecular carcinogenesis. 2015;54(11):1521-7.
Zhou F, Xu Y, Shi J, Lan X, Zou X, Wang L et al. Expression profile of E‐cadherin, estrogen receptors, and P53 in early‐onset gastric cancers. Cancer medicine. 2016;5(12):3403-11.
Etemadi A, Safiri S, Sepanlou SG, Ikuta K, Bisignano C, Shakeri R, et al. The global, regional, and national burden of stomach cancer in 195 countries, 1990–2017: a systematic analysis for the Global Burden of Disease study 2017. The Lancet Gastroenterology & Hepatology. 2020;5(1):42-54.
Tee MC, Pirozzi N, Brahmbhatt RD, Raman S, Franko J. Oncologic and surgical outcomes for gastric cancer patients undergoing gastrectomy differ by race in the United States. European Journal of Surgical Oncology. 2020.
Fricke E, Keller G, Becker I, Rosivatz E, Schott C, Plaschke S, et al. Relationship between E‐cadherin gene mutation and p53 gene mutation, p53 accumulation, Bcl‐2 expression and Ki‐67 staining in diffuse‐type gastric carcinoma. International journal of cancer. 2003;104(1):60-5.
Brito M, Williams G, Thompson H, Filipe M. Expression of p53 in early (T1) gastric carcinoma and precancerous adjacent mucosa. Gut. 1994;35(12):1697-700.
Tamura G. Alterations of tumor suppressor and tumor-related genes in the development and progression of gastric cancer. World journal of gastroenterology: WJG. 2006;12(2):192.
Dobru, D., et al., An epidemiological study of gastric cancer in the adult population referred to gastroenterology medical services in Romania–a multicentric study. Rom J Gastroenterol, 2004. 13(4): p. 275-279.
Chandanos, E. and J. Lagergren, Oestrogen and the enigmatic male predominance of gastric cancer. European journal of cancer, 2008. 44(16): p. 2397-2403.
Zhang, X.-F., et al., Surgical treatment and prognosis of gastric cancer in 2613 patients. World Journal of Gastroenterology: WJG, 2004. 10(23): p.3405.
Sargan, I., et al., Anatomic and pathological aspects in the pathology of malignant gastric tumors. Rom J Morphol Embryol, 2006. 47(2): p.163-8.
Xing X, Tang YB, Yuan G, Wang Y, Wang J, Yang Y, et al. The prognostic value of E‐cadherin in gastric cancer: a meta‐analysis. International journal of cancer. 2013;132(11):2589-96.
Dikken JL, van de Velde CJ, Coit DG, Shah MA, Verheij M, Cats A. Treatment of resectable gastric cancer. Therapeutic advances in gastroenterology. 2012;5(1):49-69.
Macdonald JS. Gastric cancer-new therapeutic options. New England Journal of Medicine. 2006;355(1):76-7.
Recio-Boiles A, Waheed A, Babiker HM. Cancer, gastric. 2017.
Sun L-B, Zhao G-J, Ding D-Y, Song B, Hou R-Z, Li Y-C. Comparison between better and poorly differentiated locally advanced gastric cancer in preoperative chemotherapy: a retrospective, comparative study at a single tertiary care institute. World journal of surgical oncology. 2014;12(1):280.
Hashemzadeh S, Pourzand A, Somi MH, Zarrintan S, Javad-Rashid R, Esfahani A. The effects of neoadjuvant chemotherapy on resectability of locally-advanced gastric adenocarcinoma: a clinical trial. International Journal of Surgery. 2014;12(10):1061-9.
Zhao Q, Li Y, Tan B, Tian Y, Jiao Z, Zhao X, et al. Effects of XELOX regimen as neoadjuvant chemotherapy on radical resection rate and prognosis in patients with advanced gastric cancer. Zhonghua zhong liu za zhi [Chinese journal of oncology]. 2013;35(10):773.
Basi A, Sohrabkhani S, Zamani F, Baghai-Wadji M, Rabiei N, Razavi S-M, et al. Comparing efficacy of preoperative neo-adjuvant chemotherapy and surgery versus surgery alone in patients with resectable gastroesophageal cancer. International journal of hematology-oncology and stem cell research. 2013;7(4):24.
Petrelli F, Berenato R, Turati L, Mennitto A, Steccanella F, Caporale M, et al. Prognostic value of diffuse versus intestinal histotype in patients with gastric cancer: a systematic review and meta-analysis. Journal of gastrointestinal oncology. 2017;8(1):148.
Hu B, El Hajj N, Sittler S, Lammert N, Barnes R, Meloni-Ehrig A. Gastric cancer: Classification, histology and application of molecular pathology. Journal of gastrointestinal oncology. 2012;3(3):251.
Singhai R, Patil VW, Jaiswal SR, Patil SD, Tayade MB, Patil AV. E-Cadherin as a diagnostic biomarker in breast cancer. North American journal of medical sciences. 2011;3(5):227.
Fondevila C, Metges J, Fuster J, Grau J, Palacin A, Castells A, et al. p53 and VEGF expression are independent predictors of tumour recurrence and survival following curative resection of gastric cancer. British journal of cancer. 2004;90(1):206-15.
Lee HK, Lee HS, Yang H-K, Kim WH, Lee KU, Choe KJ, et al. Prognostic significance of Bcl-2 and p53 expression in gastric cancer. International journal of colorectal disease. 2003;18(6):518-25.
Hiralal Sankalecha T, Gupta SJ, Gaikwad NR, Ughade SN. Correlation of P53 Expression with Various Clinicopathological Parameters of Gastric Carcinoma and Its Relationship with Survival. Journal of Gastroenterology and Hepatology Research. 2017;6(3):2370-5.
Victorzon M, Nordling S, Haglund C, Lundin J, Roberts PJ. Expression of p53 protein as a prognostic factor in patients with gastric cancer. European Journal of Cancer. 1996;32(2):215-20.
- Abstract Viewed: 95 times
- PDF Downloaded: 57 times